Upadacitinib for Crohn’s Disease: An alternative to anti-TNF Therapy?

Brian Bressler; Itay Kalisky

Authors

Brian Bressler, MD, MS, FRCPC Founder, The IBD Centre of BC Director, Advanced IBD Training Program Clinical Associate Professor of Medicine, Division of Gastroenterology, University of British Columbia, Vancouver, B.C.
Itay Kalisky, MD Staff member, IBD unit, Gastroenterology and Hepatology Division, Hebrew University and Hadassah Medical School, Jerusalem, Israel. Advanced IBD fellow, Division of Gastroenterology, University of British Columbia, Vancouver, BC.

Abstract

Since its approval for Crohn's disease, following the successful U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 trials, upadacitinib has been increasingly prescribed to Crohn's disease patients, including both biologic-naïve and biologic-experienced individuals. Although there are numerous clinical scenarios where this option is worth considering, it can be viewed as a highly reasonable alternative to anti-TNF therapy for Crohn's disease.

Author Biographies

Brian Bressler, MD, MS, FRCPC, Founder, The IBD Centre of BC Director, Advanced IBD Training Program Clinical Associate Professor of Medicine, Division of Gastroenterology, University of British Columbia, Vancouver, B.C.

Dr. Bressler is a Clinical Associate Professor of Medicine in the Department of Medicine at the University of British Columbia. Dr. Bressler is a Staff Gastroenterologist at St. Paul's Hospital in Vancouver, Canada. Dr. Bressler is the Director of the Advanced IBD training program at the University of British Columbia and is a recognized expert in inflammatory
bowel disease.

Itay Kalisky, MD, Staff member, IBD unit, Gastroenterology and Hepatology Division, Hebrew University and Hadassah Medical School, Jerusalem, Israel. Advanced IBD fellow, Division of Gastroenterology, University of British Columbia, Vancouver, BC.

Dr. Itay Kalisky currently serves as a clinical fellow at the Advanced IBD Training Program at the University of British Columbia. Dr. Kalisky acquired his BSc and MD degree from the Hebrew University and Hadassah Medical School, Jerusalem, Israel. Upon completing his residency in internal medicine, he served as a staff member at the Liver Disease Center at Sheeba Medical Centre in Ramat Gan, Israel. He became a staff member at Division of Gastroenterology and Hepatology of Hadassa Medical Centre, Jerusalem, Israel, shortly after completing his gastroenterology fellowship there. Dr. Kalisky divides his time between both clinical and research efforts in the field of IBD. He is the author and co-author of several peer-reviewed articles, participates in clinical education of residents and fellows, attends international conferences, and participates in clinical studies.

References

Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350(9):876-885. doi:10.1056/NEJMoa030815

Fu YM, Chen M, Liao AJ. A meta-analysis of adalimumab for fistula in Crohn's disease. Gastroenterol Res Pract. 2017;2017:1745692. doi:10.1155/2017/1745692

Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, et al. Efficacy of vedolizumab in fistulising Crohn's disease: exploratory analyses of data from GEMINI 2. J Crohns Colitis. 2018;12(5):621-626. doi:10.1093/ecco-jcc/jjy019

Sands BE, Gasink CR, Jacobstein DA, Gao L-L, Johanns JR, Colombel JF, et al. Fistula healing in pivotal studies of ustekinumab in Crohn's disease. Gastroenterology. 2017;152:S185. doi:10.1016/S0016-5085(17)30930-7

Vuyyuru SK, Solitano V, Narula N, Lee MJ, MacDonald JK, McCurdy JD, et al. Pharmacological therapies for the management of fistulizing Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis. 2024;18(4):589-603. doi:10.1093/ecco-jcc/jjad185

Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. doi:10.1136/gutjnl-2019-318484

Colombel JF, Irving P, Rieder F, Panaccione R, Schwartz D, Hayashi R, et al. P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn’s disease. Journal of Crohn's and Colitis. 2023;17(Supplement_1):i620-i623. doi:10.1093/ecco-jcc/jjac190.0621

Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383-1395. doi:10.1056/NEJMoa0904492

Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200-2211. doi:10.1016/s0140-6736(22)00688-2

Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn's disease. Gastroenterology. 2019;157(4):1007-1018.e1007. doi:10.1053/j.gastro.2019.06.038

Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther. 2016;43(3):317-333. doi:10.1111/apt.13475

Schreiber SW, Lim A, Lacerda AP, Allegretti JR, Watanabe K, Lukin D, et al. P630 Upadacitinib improves clinical outcomes in patients with moderate to severely active Crohn’s disease irrespective of previous failure to respond to biologics or conventional therapies. Journal of Crohn's and Colitis. 2023;17(Supplement_1):i759-i762. doi:10.1093/ecco-jcc/jjac190.0760

Feagan BG, Horst S, Dryden G, Lindsay JO, Ferrante M, Dubenco E, et al. OP17 Upadacitinib improves endoscopic outcomes in patients with moderate to severely active Crohn’s disease irrespective of previous failure to respond to biologics or conventional therapies. Journal of Crohn's and Colitis. 2023;17(Supplement_1):i22-i25. doi:10.1093/ecco-jcc/jjac190.0017

Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012;142(5):1102-1111.e1102. doi:10.1053/j.gastro.2012.01.035

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211-1259. doi:10.1016/s0140-6736(17)32154-2

Stelara® Product Monograph. Janssen Inc., Toronto, Ontario. January 5, 2023. https://pdf.hres.ca/dpd_pm/00069002.PDF

Remicade® Product Monograph. Janssen Inc., Toronto, Ontario. March 26, 2024. https://pdf.hres.ca/dpd_pm/00075118.PDF

Gordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M, et al. ECCO Guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18(1):1-37. doi:10.1093/ecco-jcc/jjad108

RINVOQ® Product Monograph. AbbVie Corporation, St-Laurent Quebec. https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/RINVOQ_PM_EN.pdf

Mohamed MF, Zeng J, Marroum PJ, Song IH, Othman AA. Pharmacokinetics of upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis phase 3 trials. Clin Pharmacol Drug Dev. 2019;8(2):208-216. doi:10.1002/cpdd.462

Colombel JF, Hisamatsu T, Atreya R, Bresso F, Thin L, Panaccione R, et al. Upadacitinib reduces Crohn's disease symptoms within the first week of induction therapy. Clin Gastroenterol Hepatol. 2024;22(8):1668-1677. doi:10.1016/j.cgh.2024.02.027

Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029-1035. doi:10.1056/nejm199710093371502

Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323-333; quiz 591. doi:10.1053/j.gastro.2005.11.030

Feagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(1):130-138.e137. doi:10.1016/j.cgh.2018.05.026

Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375(20):1946-1960. doi:10.1056/NEJMoa1602773

Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. doi:10.1053/j.gastro.2020.12.031

Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48(5):297-308. doi:10.5414/cpp48297

Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341-353. doi:10.1016/s2468-1253(19)30012-3

Buhl S, Dorn-Rasmussen M, Brynskov J, Ainsworth MA, Bendtzen K, Klausen PH, et al. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease. Scand J Gastroenterol. 2020;55(8):884-890. doi:10.1080/00365521.2020.1786852

Schoenefuss F, Hoffmann P. Serum γ-globulin and albumin concentrations predict secondary loss of response to anti-TNFα in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol. 2019;31(12):1563-1568. doi:10.1097/meg.0000000000001493

Rohatinsky N, Boyd I, Dickson A, Fowler S, Peña-Sánchez JN, Quintin CL, et al. Perspectives of health care use and access to care for individuals living with inflammatory bowel disease in rural Canada. Rural Remote Health. 2021;21(2):6358. doi:10.22605/rrh6358

Benchimol EI, Kuenzig ME, Bernstein CN, Nguyen GC, Guttmann A, Jones JL, et al. Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. Clin Epidemiol. 2018;10:1613-1626. doi:10.2147/clep.S178056

Peña-Sánchez JN, Osei JA, Rohatinsky N, Lu X, Risling T, Boyd I, et al. Inequities in rural and urban health care utilization among individuals diagnosed with inflammatory bowel disease: a retrospective population-based cohort study from Saskatchewan, Canada. J Can Assoc Gastroenterol. 2023;6(2):55-63. doi:10.1093/jcag/gwac015

Panaccione R, Lichtenstein G, Nakase H, Armuzzi A, Kucharzik T, Levy G, et al. P518 Safety of upadacitinib in ulcerative colitis: long-term data from the phase 3 open-label extension study (U-ACTIVATE). Journal of Crohn's and Colitis. 2023;17(Supplement_1):i644-i646. doi:10.1093/ecco-jcc/jjac190.0648

D'Haens G, Louis E, Loftus Jr. EV, Regueiro M, Jairath V, Magro F, et al. OP10 Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn’s disease: results from the U-ENDURE long-term extension. Journal of Crohn's and Colitis. 2024;18(Supplement_1):i17-i18. doi:10.1093/ecco-jcc/jjad212.0010

Upadacitinib for Crohn’s Disease: An alternative to anti-TNF Therapy?

Authors

Abstract

Author Biographies

Brian Bressler, MD, MS, FRCPC, Founder, The IBD Centre of BC Director, Advanced IBD Training Program Clinical Associate Professor of Medicine, Division of Gastroenterology, University of British Columbia, Vancouver, B.C.

Itay Kalisky, MD, Staff member, IBD unit, Gastroenterology and Hepatology Division, Hebrew University and Hadassah Medical School, Jerusalem, Israel. Advanced IBD fellow, Division of Gastroenterology, University of British Columbia, Vancouver, BC.

References

Downloads

Published

How to Cite

Issue

Section

License

Summary

Open Access

Licence